HIV in South Africa: why rolling out a groundbreaking new shot will miss a critical group of men

By Paul Bowen, Professor Emeritus and Senior Research Scholar in the Department of Construction Economics and Management, University of Cape Town
Rajen Govender, Professor Extraordinaire at the Institute for Social and Health Sciences, University of South Africa; University of Cape Town

The first shipment of Lenacapavir, a long-acting injectable that prevents HIV with two shots a year, arrived in South Africa from the United States in early April 2026. Clinical trials showed close to 100% efficacy. The rollout, expected to begin in June 2026, prioritises…

Read complete article

~	Poop tests and blood tests join colonoscopy as options for colorectal cancer screening

~	Who is talking about artificial intelligence in Ecuador?

~	When ICE ramped up enforcement, US-born workers didn’t see any economic gains

~	Chinese American teens experience depression, anxiety at higher rates than peers – here’s why their parents may miss the warning signs

~	I’ve been studying racist costume parties for a decade, and colleges are failing at educating the students about why they’re wrong

~	Scientists used a method from ecology to identify whether icy moons could hold conditions for life

~	PFAS leave fingerprints in your blood – researchers are figuring out how forever chemicals transform in your body to read these clues

~	Far removed from today’s global juggernaut, soccer was born in the well-heeled boarding schools of 19th-century England

~	Better patient-nurse relationships can transform mental health care – and make hospital stays shorter

~	Why Africa – and the world – remain dangerously unprepared for the next pandemic